Evidence map›Paper›PMID 37182789›Full record

ArticleMetabolism: clinical and experimental2023

Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis.

Mari C Vázquez-Borrego, Mercedes Del Río-Moreno, Maxim Pyatkov, André Sarmento-Cabral, Mariyah Mahmood, Natalie Pelke, Magdalena Wnek, Jose Cordoba-Chacon, David J Waxman, Michelle A Puchowicz and 2 more

Open access · greenAbstract read
In one paragraph

Article in Metabolism: clinical and experimental, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Growth Hormone Promotes Hepatic Triglyceride Export in Humans.The Journal of clinical endocrinology and metabolism · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Liver-specific actions of GH and IGF1 that protect against MASLD.Nature reviews. Endocrinology · 2025 · on this map
    Review
  16. Article
  17. Article
  18. Growth hormone receptor in VGLUT2 or Sim1 cells regulates glycemia and insulin sensitivity.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Mari C Vázquez-BorregoDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.
Mercedes Del Río-MorenoDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.
Maxim PyatkovDepartment of Biology & Bioinformatics Program, Boston University, Boston, MA, United States of America.
André Sarmento-CabralDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.
Mariyah MahmoodDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.
Natalie PelkeDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.
Magdalena WnekDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.
Jose Cordoba-ChaconDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.
David J WaxmanDepartment of Biology & Bioinformatics Program, Boston University, Boston, MA, United States of America.
Michelle A PuchowiczDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, United States of America.
Owen P McGuinnessDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, United States of America.
Rhonda D KinemanDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America. Electronic address: kineman@uic.edu.
University of Massachusetts Boston · USUniversity of Tennessee Health Science Center · USVanderbilt University · US

Funding

Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Marcela Brissova · 2012 to 2026
$29.3M
Vanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3M
Growth Hormone Regulation of Sex Differences in Liver MetabolismR01DK121998 · NIDDK · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WAXMAN, DAVID J · 2019 to 2023
$2.5M
Hormonal Regulation of Liver MetabolismR01DK116878 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KINEMAN, RHONDA D · 2019 to 2022
$1.5M
Gas Chromotograph- Triple Quadrupole Tandem Mass Spectrometer (GC-QqQ)S10OD025199 · OD · VANDERBILT UNIVERSITY · PI YOUNG, JAMEY D. · 2018 to 2018
$365k
Hormonal control of NASH development and progressionI01BX004448 · VA · JESSE BROWN VA MEDICAL CENTER · PI KINEMAN, RHONDA D · 2019 to 2025
–
BLRD Research Career Scientist Award ApplicationIK6BX005382 · VA · JESSE BROWN VA MEDICAL CENTER · PI KINEMAN, RHONDA D · 2021 to 2025
–
BLRD VA I01 BX004448BLRD VA IK6 BX005382NIDDK NIH HHS P30 DK020593NIDDK NIH HHS R01 DK116878NIDDK NIH HHS R01 DK121998NIDDK NIH HHS U2C DK059637NIH HHS S10 OD025199
6 · The paper itself

Abstract

backgroundEvidence is accumulating that growth hormone (GH) protects against the development of steatosis and progression of non-alcoholic fatty liver disease (NAFLD). GH may control steatosis indirectly by altering systemic insulin sensitivity and substrate delivery to the liver and/or by the direct actions of GH on hepatocyte function. APPROACH: To better define the hepatocyte-specific role of GH receptor (GHR) signaling on regulating steatosis, we used a mouse model with adult-onset, hepatocyte-specific GHR knockdown (aHepGHRkd). To prevent the reduction in circulating insulin-like growth factor 1 (IGF1) and the subsequent increase in GH observed after aHepGHRkd, subsets of aHepGHRkd mice were treated with adeno-associated viral vectors (AAV) driving hepatocyte-specific expression of IGF1 or a constitutively active form of STAT5b (STAT5b

resultsChow-fed male aHepGHRkd mice developed steatosis associated with an increase in hepatic glucokinase (GCK) and ketohexokinase (KHK) expression and de novo lipogenesis (DNL) rate, in the post-absorptive state and in response to refeeding after an overnight fast. The aHepGHRkd-associated increase in hepatic KHK, but not GCK and steatosis, was dependent on hepatocyte expression of carbohydrate response element binding protein (ChREBP), in re-fed mice. Interestingly, under clamp conditions, aHepGHRkd also increased the rate of DNL and expression of GCK and KHK, but impaired insulin-mediated suppression of hepatic glucose production, without altering plasma NEFA levels. These effects were normalized with AAV-mediated hepatocyte expression of IGF1 or STAT5b

conclusionThese studies demonstrate hepatocyte GHR-signaling controls hepatic glycolysis, DNL, steatosis and hepatic insulin sensitivity indirectly (via IGF1) and directly (via STAT5b). The relative contribution of these indirect and direct actions of GH on hepatocytes is modified by insulin and nutrient availability. These results improve our understanding of the physiologic actions of GH on regulating adult metabolism to protect against NAFLD progression.

Indexed as

Human Growth HormoneInsulin ResistanceNon-alcoholic Fatty Liver DiseaseAnimalsGlucoseGlycolysisGrowth HormoneInsulinLipogenesisLiverMaleMiceReceptors, SomatotropinGlucoseGrowth HormoneHuman Growth HormoneInsulinReceptors, Somatotropinde novo lipogenesis (DNL)GlucokinaseGrowth hormone (GH)Insulin like growth factor 1 (IGF1)LiverSTAT5b

Identifiers

PMID37182789
PMCPMC10843389
OpenAlexW4376257027

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.